luspatercept-aamt

luspatercept-aamt (REBLOZYL) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.

REBLOZYL is a marketed brand name for luspatercept-aamt. Check FDA Drugs@FDA for the current US label holder and prescribing information.

luspatercept-aamt has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.